Clomiphene citrate therapy for luteal phase defect

The incidence of luteal phase defects in 366 infertility patients was 12.7%. Life-table analysis was used for determination of the conception rate with clomiphene citrate therapy, and with this method, evidence was found for the presence of two subgroups with respect to response. The crude conception rate was 40.9%. In a group of patients with a luteal phase defect and no other infertility factors, those that conceived had a significantly larger mean biopsy delay than those who did not (6.28 days versus 4.32; P less than 0.02). In a group with a histologic delay of 5 days or more, the conception rate was 79%, while the rate was only 8.9% in those with a less severe deficit (P less than 0.001). Theoretic considerations for clomiphene citrate therapy are discussed. The incidence of luteal phase defects in 366 infertility patients was 12.7%. Life table analysis was used for determination of the conception rate with clomiphene citrate therapy, and with this method, evidence was found for the presence of 2 subgroups with respect to response. The crude conception rate was 40.9%. In a group of patients with a luteal phase defect and no other infertility factors, those who conceived had a significantly larger mean biopsy delay than those who did not (6.28 days vs 4.32; P0.02). In a group with a histologic delay of 5 or more days, the conception rate was 79%, while the rate was only 8.9% in those with a less severe deficit (P0.001). Theoretic considerations for clomiphene citrate therapy are discussed.